1. Home
  2. CLM vs MESO Comparison

CLM vs MESO Comparison

Compare CLM & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cornerstone Strategic Value Fund Inc. New

CLM

Cornerstone Strategic Value Fund Inc. New

HOLD

Current Price

$7.31

Market Cap

2.3B

Sector

Finance

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$14.75

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLM
MESO
Founded
N/A
2004
Country
United States
Australia
Employees
N/A
81
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.2B
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
CLM
MESO
Price
$7.31
$14.75
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
2.2M
250.8K
Earning Date
01-01-0001
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$644.56
Revenue Next Year
N/A
$38.70
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.57
$9.61
52 Week High
$8.53
$21.50

Technical Indicators

Market Signals
Indicator
CLM
MESO
Relative Strength Index (RSI) 34.82 39.40
Support Level $7.29 $14.74
Resistance Level $8.22 $16.33
Average True Range (ATR) 0.13 0.50
MACD -0.01 -0.02
Stochastic Oscillator 13.46 45.65

Price Performance

Historical Comparison
CLM
MESO

About CLM Cornerstone Strategic Value Fund Inc. New

Cornerstone Strategic Value Fund Inc is a closed-end management investment company. The fund's objective is to seek long-term capital appreciation through investments in equity securities of U.S. and non-U.S. companies. It invests in various sectors, which include financials, information technology, healthcare, consumer discretionary, industrials, utilities, energy, telecommunication services, materials, and other sectors.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: